James R. Sulat is on the board of Valneva SE, Arch Therapeutics, Inc. and Exicure, Inc.
He previously occupied the position of Director, Chief Executive & Financial Officer for Maxygen, Inc., Interim Chief Financial Officer & SEVP at R.R. Donnelley & Sons Co. and Senior Executive Vice President at Moore Wallace, Inc. (a subsidiary of R.R. Donnelley & Sons Co.), Director at Momenta Pharmaceuticals, Inc., Director at Memory Pharmaceuticals Corp., Chief Financial Officer & Vice President of Chiron Corp. and Chief Financial Officer of Stanford Health Care.
Mr. Sulat received an undergraduate degree from Yale University and an MBA and a graduate degree from Stanford University.